FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($0.28), $0.31 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $43.95 million versus the consensus estimate of $27.74 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.